FIELD: pharmaceuticals; medicine; ophthalmology.
SUBSTANCE: invention is intended for treating macular edema. Pharmaceutical composition for treating macular edema contains an integrin-inhibiting peptide, which consists of Glicinyl-Arginyl-Glycynyl-Cysteic acid-Threonyl-Proline-COOH or a pharmaceutically acceptable salt thereof. In one embodiment, said peptide is a linear peptide and has the structural formula: 
EFFECT: use of the invention provides macular edema treatment by inhibiting angiogenesis.
11 cl, 8 tbl, 11 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS AND METHODS FOR INHIBITION OF CELLULAR ADHESION OR DIRECTION OF DIAGNOSTIC OR THERAPEUTIC AGENTS TO RGD BINDING SITES | 2010 |
|
RU2642625C2 |
| COMPOSITIONS AND METHODS FOR ANGIOGENESIS SUPPRESSION | 2010 |
|
RU2786127C2 |
| PEPTIDES FOR INHIBITING ANGIOGENESIS | 2016 |
|
RU2708375C2 |
| USE OF VEGF ANTAGONIST FOR TREATING RETINOPATHY OF PREMATURITY | 2014 |
|
RU2676303C2 |
| MEANS FOR TREATMENT OF DISEASE WITH MACULAR OEDEMA DUE TO EXCESSIVE VEGF-A EXPRESSION | 2016 |
|
RU2669787C2 |
| LIPOSOMAL PREPARATIONS | 2013 |
|
RU2817350C2 |
| LIPOSOME FORMULATIONS | 2013 |
|
RU2680096C2 |
| FLUORINE-CONTAINING INTEGRIN ANTAGONISTS | 2014 |
|
RU2698195C2 |
| APPLICATION OF ANTAGONIST VEGF IN TREATMENT OF CHORIORETINAL NEOVASCULAR DISTURBANCES AND DISORDERS OF PENETRATION IN PEDIATRIC PATIENTS | 2014 |
|
RU2676274C2 |
| OPTIMIZED OPTIONS OF ANTI-VEGF ANTIBODIES | 2016 |
|
RU2763916C2 |
